NGM Bio Announces Multiple Aldafermin Presentations at Upcoming AASLD The Liver Meeting®, including Late-Breaking Oral Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy